The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:1660-1662 October 18, 2007 Number 16
NextNext

Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Shiffman, M. L.
-PubMed Citation
To the Editor: Shiffman et al. (July 12 issue)1 report the results of the ACCELERATE study, which compared 16 weeks with 24 weeks of peginterferon alfa-2a and ribavirin in patients with hepatitis C virus (HCV). The difference in the rate of sustained virologic response after the standard treatment duration as compared with the shorter duration was 2 percentage points higher than the preestablished 6% margin for noninferiority. This led the investigators to endorse a treatment duration of 24 weeks, even though more patients in the 24-week group (absolute difference, 6%) were unable to tolerate this schedule. By considering a 12.5% . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.